Black Diamond Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Mark A. Velleca and CFO Erika Jones certified the Q2 2026 10-Q (period ended June 30, 2026) filed August 5, 2026. Both officers attested that financial statements fairly present the company's condition and results, disclosure controls are effective, and no material weaknesses or fraud were identified. This is standard Sarbanes-Oxley certification with no substantive business changes, transactions, or financial metrics disclosed in the excerpt provided.
Why this rating
Routine SOX certifications are boilerplate; no business events, deals, or financial data disclosed. Administrative filing only.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.